SORRENTO THERAPEUTICS, INC.

Basic Information

6042 CORNERSTONE CT, STE B
SAN DIEGO, CA, 92121-4746

http://www.sorrentotherapeutics.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 832545805
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 65


  1. Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis

    Amount: $224,823.00

    DESCRIPTION (provided by applicant): New anti-fibrotic drugs are needed to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, chronically debilitating clinical syndrome with unknown etio ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Targeting of Myc-Max dimerization for the treatment of cancer

    Amount: $224,550.00

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, ...

    STTR Phase I 2014 Department of Health and Human Services
  3. Human monoclonal antibodies for prevention of S. aureus infections

    Amount: $1,997,627.00

    DESCRIPTION provided by applicant Using mouse monoclonal antibodies mAbs raised against the mediators of quorum sensing QS the Auto Inducing Peptides AIPs researchers at The Scripps Researc ...

    STTR Phase II 2014 Department of Health and Human Services National Institutes of Health
  4. Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

    Amount: $586,535.00

    DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use Ho ...

    STTR Phase I 2014 Department of Health and Human Services National Institutes of Health
  5. Human monoclonal antibodies for prevention of S. aureus infections

    Amount: $597,832.00

    DESCRIPTION (provided by applicant): Using mouse monoclonal antibodies (mAbs) raised against the mediators of quorum sensing (QS), the Auto-Inducing Peptides (AIPs), researchers at The Scripps Researc ...

    STTR Phase I 2012 Department of Health and Human Services
  6. A vaccine against Clostridium difficile infections

    Amount: $598,689.00

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our vaccination strategies targeting Clostridium difficile to prevent or treat infections. W ...

    STTR Phase I 2011 Department of Health and Human Services
  7. Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat ...

    STTR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government